ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

Klaas Heinemann

Managing Director

Klaas Heinemann

Klaas Heinemann is a physician and epidemiologist who has headed ZEG Berlin since 2009 and sits on the Kantar Health Europe management board.  The principal investigator for many studies, Klaas provides strategic direction as ZEG-Berlin diversifies beyond women’s health studies to bring its data methodology to other realms of health.

 

Klaas trained in internal medicine at Charite University Hospital, Berlin before completing postgraduate masters degrees in business and administration (Berlin School of Economics, Berlin), and epidemiology (London School of Hygiene and Tropical Medicine, London). Prior to his appointment as managing director, Klaas was an external consultant for ZEG Berlin. Previously he worked in the US and Germany as a Medical Expert in Global Medical Affairs at Schering AG and later Bayer Pharma, planning and managing clinical research focusing on Phase III clinical studies and post-market phase IV study design.

Publications

Bauerfeind Anja, von Stockum Sophia, Boehnke Tanja, Heinemann Klaas, Venous Thromboembolic Risk of Estradiol Valerate–Dienogest Compared with Ethinyl Estradiol–Levonorgestrel Combined Oral Contraceptives. Obstetrics & Gynecology. 2024; 10.1097/AOG.0000000000005509.
Becker Kerstin, Heinemann Klaas, Imthurn Bruno, Marions Lena, Moehner Sabine, Gerlinger Christoph, Serrani Marco, Faustmann Thomas, Real world data on symptomology and diagnostic approaches of 27,840 women living with endometriosis. Scientific Reports. 2021; 10.1038/s41598-021-99681-3.
Barnett Clare, Bauerfeind Anja, von Stockum Sophia, Grimes David A., Heinemann Klaas, Comparing the Cardiovascular Risk of Norethindrone Acetate & Levonorgestrel Pills: Is There a Difference? [10I]. Obstetrics & Gynecology. 2020; Volume 135 - Issue - p 94S. 10.1097/01.AOG.0000664136.96902.7e.
Dinger Jürgen, Heinemann Klaas, Transatlantic active surveillance of cardiovascular safety (TASC) of an Etonogestrel/Ethinylestradiol-containing vaginal ring. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Heinemann Klaas, Dinger Jürgen, Bardenheuer Kristina, The safety of oral contraceptives in adolescents. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Intrauterine devices and risk of uterine perforations: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S2) 45. DOI 10.1002.
Heinemann Klaas, Assmann Anita, Long term active surveillance study for oral contraceptives (LASS): final results on cardiovascular safety. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 360. DOI 10.1002.
Heinemann Klaas, Assmann Anita, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 365. DOI 10.1002.
Dennerstein L, Lehert P, Heinemann Klaas, Epidemiology of premenstrual symptoms and disorders. Menopause International. 2012; Jun;18(2):48-51.
Heinemann Lothar A , Do Minh Thai, Heinemann Klaas, Lindemann M , Filonenko A, Intercountry assessment of the impact of severe premenstrual disorders on work and daily activities. Health Care Women International. 2012; Feb;33(2):109-24.
Heinemann Klaas, Heinemann Lothar A , Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.. J Fam Plann Reprod Health Care. 2011; Jul;37(3):132-5. 10.1136/jfprhc-2011-14524.
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Complications associated with unintended pregnancies under IUD use: results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 125.
Heinemann Klaas, EURAS-HRT: study design and baseline characteristics - international menopause society. The Journal of Adult Women`s Health & Medicine. 2011; Vol. 14 Supplement 1: 214.
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Intrauterine devices and the risk of uterine perforation: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 233.
Heinemann Klaas, Barnett Clare, Dinger Jürgen, Risk factors for uterine perforations during IUD insertion: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 138.
Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 181.
Dennerstein L, Lehert P, Heinemann Klaas, Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause International. 2011; Sep: 17(3):96-101. 10.1258/mi.2011.011028.
Dennerstein L, Lehert P, Heinemann Klaas, Global study of women's experiences of premenstrual symptoms and their effects on daily life. Menopause International. 2011; Sep: 17(3):88-95. 10.1258/mi.2011.011027.
Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: Interim results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2010; 19:S31-32.
Heinemann Klaas, Problems associated with comprehensive detection/validation of unexpected ADRs in a population. PRM Newsletter. 2010; Apr 2010;5:1-3,9-1.
Dennerstein L, Lehert P, Bäckström T, Heinemann Klaas, The effect of premenstrual symptoms on activities of daily life. Fertil Steril. 2010; Aug;94(3):1059-64.. 10.1016/j.fertnstert.2009.04.023.
Bardenheuer Kristina, Dinger Jürgen, Assmann Anita, Heinemann Klaas, Leddin Janko, Drug utilization study on the prescribing indications of oral contraceptives in croatia. Pharmacoepidemiology and Drug Safety. 2010; 19:S55.
Bäckström T, Heinemann Klaas, Nyberg S, Hammarbäck S, Definition and prevalence of premenstrual syndromes. Gynaecology Forum. 2009; 14(3).
Heinemann Klaas, Rübig A, Strothmann A, Nahum GG, Heinemann Lothar A , Prevalence and opinions of hormone therapy prior to the Women’s Health Initiative: a multinational survey in four continents. J Women’s Health. 2008; 17:1-16.
Heinemann Klaas, Saad F, Wiesemes M, Heinemann Lothar A , Expectations towards a novel MFC and potential user types. Results of a multinational survey. J Andrology. 2005; 26(2): 155-62.
Heinemann Klaas, Saad F, Wiesemes M, Heinemann Lothar A , Attitudes toward male fertility control; a multinational survey in four continents. Human Reproduction. 2005; 20 (2): 549-56.
Heinemann Lothar A , Potthoff P, Heinemann Klaas, Pauls Alfred, Ahlers C J, Saad F, Scale for Quality of Sexual Function (QSF) as an outcome measure for both genders?. J Sex Med. 2005; 2:82-95.
Heinemann Lothar A , Saad F, Heinemann Klaas, Do Minh Thai, Can results of the AMS scale predict those of screening scales for androgen deficiency?. Aging Male. 2004; 7:211-18.
Heinemann Klaas, Alexander Ruebig Alexander, Potthoff P, Schneider HPG, Strelow Frank, Heinemann Lothar A , Do Minh Thai, The Menopause Rating Scale: A methodological review. Health and Quality of Life Outcomes. 2004; 2:45 (2 September 2004). 10.1186/1477-7525-2-45.
Heinemann Klaas, Assmann Anita, Lewis Michael, Garbe E, Heinemann Lothar A , Teichmann A T, Trend der HRT Nutzung in Deutschland 1980-1999. Ergebnisse der Deutschen Kohortenstudie zur Frauengesundheit. 2002; 43:508-511.
Heinemann Lothar A , Assmann Anita, Heinemann Klaas, Use of oral contraceptives containing dienogest and risk of venous thromboembolism; an extended summary report. Life and Medical Science Online. 2001; 2.
Heinemann Klaas, Heinemann Lothar A , Do Minh Thai, Möhner M, Heuchert G E, Occupational exposure and liver cancer in women: results of the Multicentre International Liver Tumour Study (MILTS). Occup Med (Lond). 2000; Aug;50(6):422-9.